Familial Hypercholesterolemia in the Danish General Population: Prevalence, Coronary Artery Disease, and Cholesterol-Lowering Medication
The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Context: The diagnosis of familial hypercholesterolemia (FH) can be made using the Dutch Lipid Clinic Network criteria. This employs the personal and family history of premature coronary artery disease and hypercholesterolemia and the presence of a pathogenic mutation in the low-density lipoprotein receptor (LDLR) and apolipoprotein B (APOB) genes. Objective: We employed this tool to investigate the prevalence of FH and the associations between FH and coronary artery disease and cholesterol-lowering medication in the Copenhagen General Population Study. Setting: The study was of an unselected, community-based population comprising 69,016 participants. Main Outcome Measures: FH (definite/probable) was defined as a Dutch Lipid Clinic Network score higher than 5. Coronary artery disease was myocardial infarction or angina pectoris. Results: The prevalence of FH was 0.73% (one in 137). Of participants with FH, 20% had an LDLR or APOB mutation. The prevalence of coronary artery disease among FH participants was 33%. Only 48% of subjects with FH admitted to taking cholesterol-lowering medication. The odds ratio for coronary artery disease off cholesterol-lowering medication was 13.2 (10.0–17.4) in definite/probable FH compared with non-FH subjects, after adjusting for age, gender, body mass index, hypertension, metabolic syndrome and diabetes, and smoking. The corresponding adjusted odds ratio for coronary artery disease in FH subjects on cholesterol-lowering medication was 10.3 (7.8–13.8). Conclusion: The prevalence of FH appears to be higher than commonly perceived in a general population of white Danish individuals, with at least half of affected subjects not receiving cholesterol-lowering medication. The very high risk of coronary artery disease irrespective of use of medication reflects the extent of underdiagnosis and undertreatment of FH in the community and primary care.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The frequency of HeFH in the population has earlier been estimated at 1/500; however, recent studies from whole populations suggest that the frequency is higher, in some populations as high as 1/137. 297”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [297]
Citations
Cites
Alberti, K. G. M. M., Eckel, R. H., Grundy, S. M., Zimmet, P. Z., Cleeman, J. I., Donato, K. A., Fruchart, J.-C., James, W. P. T., Loria, C. M., & Smith, S. C. (2009) · Circulation · doi:10.1161/circulationaha.109.192644 · Cited by 14,860
ESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549
(2003) · Journal of Hypertension · doi:10.1097/00004872-200311000-00002 · Cited by 2,672
Nordestgaard, B. G., Benn, M., Schnohr, P., & Tybjærg-Hansen, A. (2007) · JAMA · doi:10.1001/jama.298.3.299 · Cited by 2,058
Self-citationJones, P. H., Davidson, M. H., Stein, E. A., Bays, H. E., McKenney, J. M., Miller, E., Cain, V. A., & Blasetto, J. W. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00530-7 · Cited by 1,398
Genetically elevated C-reactive protein and ischemic vascular disease
Zacho, J., Tybjærg-Hansen, A., Jensen, J. S., Grande, P., Sillesen, H., & Nordestgaard, B. G. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707402 · Cited by 839
Self-citationKotseva, K., Wood, D., Backer, G. D., Bacquer, D. D., Pyörälä, K., Keil, U., & EUROASPIRE Study Group (2009) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/hjr.0b013e3283294b1d · Cited by 812
Efficacy of statins in familial hypercholesterolaemia: a long term cohort study
Versmissen, J., Oosterveer, D. M., Yazdanpanah, M., Defesche, J. C., Basart, D. C. G., Liem, A. H., Heeringa, J., Witteman, J. C., Lansberg, P. J., Kastelein, J. J. P., et al. (2008) · BMJ · doi:10.1136/bmj.a2423 · Cited by 721
ESC/EAS Guidelines for the management of dyslipidaemias
Catapano, A. L., Reiner, Ž., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.06.028 · Cited by 706
Research works printed but not linked: 1
- World Health Organization, 1999, Familial hypercholesterolaemia (FH)
Cited by
Items 401–500 of 632
Cholesterol Levels in Genetically Determined Familial Hypercholesterolaemia in Russian Karelia
Korneva, V. A., Kuznetsova, Т. Y., Bogoslovskaya, T. Y., Polyakov, D. S., Vasilyev, V. B., Orlov, A. V., & Mandelshtam, M. Y. (2017) · Cholesterol · doi:10.1155/2017/9375818 · Cited by 9
Tanaka, N., Teramoto, T., & Yokoyama, S. (2018) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.46979 · Cited by 8
Shi, H.-W., Yang, J., Wang, Y., Li, W., Guo, Y., Gao, Y., Tang, Y., Li, J., Wu, N., & Yang, Y. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.00113 · Cited by 9
Reiman, A., Pandey, S., Lloyd, K. L., Dyer, N. P., Khan, M., Crockard, M. A., Latten, M. J., Watson, T. L., Cree, I. A., & Grammatopoulos, D. K. (2016) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/0004563216629170 · Cited by 8
Meng, R., Shi, F., Zhang, B., Li, C., Wang, J., Song, L., Zhang, L., & Shen, M. (2025) · BMC Medicine · doi:10.1186/s12916-025-03966-7 · Cited by 7
Jensen, J. S., Weeke, P. E., Bang, L. E., Høfsten, D. E., Ripa, M. S., Schjerning, A.-M., Theilade, J., Køber, L., Gislason, G., & Pallisgaard, J. L. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-022702 · Cited by 8
Beheshti, S. O., Madsen, C. M., Varbo, A., & Nordestgaard, B. G. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-02261 · Cited by 8
Self-citationTeramoto, T., Sawa, T., Iimuro, S., Inomata, H., Koshimizu, T., Sakakibara, I., & Hiramatsu, K. (2020) · Cardiovascular Therapeutics · doi:10.1155/2020/5936748 · Cited by 12
How Can We Identify Very High-Risk Heterozygous Familial Hypercholesterolemia?
Kataoka, Y., Funabashi, S., Doi, T., & Harada-Shiba, M. (2022) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv17063 · Cited by 8
Novel Therapies for Familial Hypercholesterolemia
Parizo, J. T., Sarraju, A., & Knowles, J. W. (2016) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-016-0486-2 · Cited by 7
Systematic Identification of Familial Hypercholesterolaemia in Primary Care—A Systematic Review
Silva, L., Qureshi, N., Abdul-Hamid, H., Weng, S. F., Kai, J., & Leonardi‐Bee, J. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11040302 · Cited by 9
Europe aspires to set the record straight on familial hypercholesterolaemia
Watts, G. F., Pang, J., & Santos, R. D. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.04.016 · Cited by 7
Self-citationAngeborene Störungen im Lipoproteinstoffwechsel
März, W., Grammer, T. B., Delgado, G., & Kleber, M. E. (2017) · Herz · doi:10.1007/s00059-017-4578-x · Cited by 7
Establishing a national screening programme for familial hypercholesterolaemia in Lithuania
Petrulionienė, Ž., Gargalskaite, U., Kutkienė, S., Staigytė, J., Čerkauskienė, R., & Laucevičius, A. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.06.012 · Cited by 13
IuA, K. (2019) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2018-14-6-922-934 · Cited by 8
Familial hypercholesterolaemia: a common disease
Ray, K. K., & Hovingh, G. K. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw130 · Cited by 10
Familial Hypercholesterolemia, as an Independent Risk of Cerebral Small Vessel Disease
Murata, H., Hattori, Y., Noda, K., Hori, M., Ogata, S., Nakaoku, Y., Morita, Y., Nishimura, K., Nagai, A., Harada‐Shiba, M., et al. (2025) · Stroke · doi:10.1161/strokeaha.124.050070 · Cited by 6
Shen, T., Fu, Q., Luo, R., Wan, Y., & Jiang, L. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1237261 · Cited by 7
de Sá, A. C. M. G. N., Gomes, C. S., Prates, E. J. S., Brant, L. C. C., & Malta, D. C. (2023) · Scientific Reports · doi:10.1038/s41598-023-47692-7 · Cited by 7
Advances in familial hypercholesterolemia
Paquette, M., & Baass, A. W. (2024) · Advances in clinical chemistry · doi:10.1016/bs.acc.2024.02.004 · Cited by 6
Algorithm for detection and screening of familial hypercholesterolemia in Lithuanian population
Aliošaitienė, U., Petrulionienė, Ž., Rinkūnienė, E., Mainelis, A., Brazdziuniene, E., Smailytė, U., Sileikiene, V., & Laucevičius, A. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02124-x · Cited by 6
The hinterland of familial hypercholesterolaemia: what do we not know?
Wierzbicki, A. S., & Watts, G. F. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000238 · Cited by 7
Self-citationPage, M. M., Bell, D. A., & Watts, G. F. (2019) · Clinical Genetics · doi:10.1111/cge.13685 · Cited by 6
Self-citationBarkas, F., Rizos, C. V., Liamis, G. L., Skoumas, I., Garoufi, A., Rallidis, L. S., Kolovou, G. D., Τζιόμαλος, Κ., Skalidis, E. I., Sfikas, G., et al. (2024) · Journal of clinical lipidology · doi:10.1016/j.jacl.2024.01.005 · Cited by 9
Landmark position paper on paediatric familial hypercholesterolaemia from the EAS Consensus Panel
Stock, J. K. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.06.021 · Cited by 6
Familial Hypercholesterolaemia in the Era of Genetic Testing
Hughes, D., Viljoen, A., & Wierzbicki, A. S. (2016) · Current Cardiology Reports · doi:10.1007/s11886-016-0723-z · Cited by 6
Focus on PCSK9 Inhibitors: From Genetics to Clinical Practice
Sabatine, M. S., Underberg, J. A., Koren, M. J., & Baum, S. J. (2016) · Postgraduate Medicine · doi:10.1080/00325481.2016.1208895 · Cited by 6
Burden of familial heterozygous hypercholesterolemia in Uzbekistan: Time is muscle
Shek, A. B., Alieva, R. B., Kurbanov, R. D., Hoshimov, S. U., Nizamov, U. I., Abdullaeva, G., & Nagay, A. V. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.08.016 · Cited by 6
Inhibiteurs de PCSK9 : quelle place dans la prise en charge actuelle des dyslipidémies ?
Sabouret, P. F., Farnier, M., & Puymirat, É. (2019) · La Presse Médicale · doi:10.1016/j.lpm.2019.01.009 · Cited by 9
Ferrières, J., Banks, V., Pillas, D., Giorgianni, F., Gantzer, L., Lekens, B., Ricci, L., Dova-Boivin, M., Chauny, J.-V., Villa, G., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0255345 · Cited by 7
Eid, W., Sapp, E. H., Flerlage, E., & Nolan, J. R. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.121.020800 · Cited by 7
Li, B., Hao, P., Zhang, Y., Yin, R.-H., Kong, Q., Cai, X., Zhao, Z., Qi, J., Li, Y., Xiao, J., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10762 · Cited by 6
GENETIC RESEARCHES AMONG MALAYSIAN FAMILIAL HYPERCHOLESTEROLAEMIC POPULATION
Al-Khateeb, A. M., & Al-Talib, H. I. (2016) · Journal of Health and Translational Medicine · doi:10.22452/jummec.vol19no2.1 · Cited by 8
Silva, P. R. D. S., Jannes, C. E., de Oliveira, T. G. M., Gómez, L. M. G., Krieger, J. E., Santos, R. D., & Pereira, A. C. (2018) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20180156 · Cited by 10
Chen, Y., Chen, I., Chen, Y., Hsiao, T., Wei, C., Chuang, H., Lin, W.-W., & Lin, C. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.994662 · Cited by 6
Clinical familial hypercholesterolemia, heart healthy dietary adherence, and cardiovascular risk
Toft-Nielsen, F., Emanuelsson, F., Nordestgaard, B. G., & Benn, M. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.120463 · Cited by 9
Self-citationSilva, P. R. D. S., Jannes, C. E., de Oliveira, T. G. M., Krieger, J. E., Santos, R. D., & Pereira, A. C. (2022) · Journal of clinical lipidology · doi:10.1016/j.jacl.2022.01.005 · Cited by 6
Marquina, C., Morton, J. I., Brett, T., Lloyd, M., Radford, J. C., Heal, C. F., Hespe, C. M., Gill, G., SULLIVAN, D. R., Zomer, E., et al. (2023) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.122.003842 · Cited by 5
Self-citationHammer‐Hansen, S., Stoltze, U. K., Bartels, E. D., Hansen, T. V. O., Byrjalsen, A., Tybjærg‐Hansen, A., Juul, K., Schmiegelow, K., Tfelt‐Hansen, J., Bundgaard, H., et al. (2024) · European Journal of Human Genetics · doi:10.1038/s41431-024-01618-7 · Cited by 5
Vassy, J. L., Brunette, C. A., Yi, T., Harrison, A., Cardellino, M. P., Assimes, T. L., Christensen, K. D., Devineni, P., Gaziano, J. M., Gong, X., et al. (2024) · American Heart Journal · doi:10.1016/j.ahj.2024.04.021 · Cited by 5
Rogozik, J. K., Rokicki, J. K., Grabowski, M., & Główczyńska, R. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13185615 · Cited by 6
Češka, R., Paragh, G., Reiner, Ž., Banach, M., Tokgözoğlu, L. S., Susekov, A. V., Rašlová, K., Freiberger, T., Vohnout, B., Rynkiewicz, A., et al. (2017) · Vnitřní lékařství · doi:10.36290/vnl.2017.008 · Cited by 6
Yaman, S., Özdemir, D., Akman, B. T., Çakır, B., & Ersoy, O. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1805212 · Cited by 5
Shu, H., Zhang, W., Zheng, C.-C., Gao, M.-Y., Li, Y.-C., & Wang, Y. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.650077 · Cited by 5
Brett, T., Radford, J. C., Heal, C. F., Hespe, C. M., Garton‐Smith, J., Kirke, A. B., Chan, D. C., Pang, J., & Watts, G. F. (2021) · Australian Journal of General Practice · doi:10.31128/ajgp-02-21-5836 · Cited by 5
Self-citationGenetically Engineered Hamster Models of Dyslipidemia and Atherosclerosis
Xian, X., Wang, Y., & Liu, G. E. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-1924-7_26 · Cited by 7
Vasilyev, V. B., Zakharova, F. M., Bogoslovskaya, T. Y., & Mandelshtam, M. Y. (2022) · Vavilov Journal of Genetics and Breeding · doi:10.18699/vjgb-22-38 · Cited by 5
Familial hypercholesterolemia in childhood and adolescents: A hidden reality
Plana, N., Rodríguez-Borjabad, C., Ibarretxe, D., & Masana, L. (2017) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2016.11.002 · Cited by 8
Soran, H., Cooper, J. A., Durrington, P. N., Capps, N. E., McDowell, I. F. W., Humphries, S. E., & Neil, A. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000692 · Cited by 5
Rizos, C. V., Liberopoulos, E. N., FASA, Athyros, V. G., Bilianou, E., Chrousos, G. P., Garoufi, A., Kolovou, G. D., Kotsis, V., Rallidis, L., et al. (2017) · HORMONES · doi:10.14310/horm.2002.1749 · Cited by 8
Molnar, S., Scharnagl, H., Delgado, G. E., Krämer, B. K., Laufs, U., März, W., Kleber, M. E., & Katzmann, J. L. (2024) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcad075 · Cited by 4
Climent, E., González-Guerrero, A., Marco-Benedí, V., García-Andreu, M.-D.-M., Mediavilla-García, J. D., Tembra, M. S., Benaiges, D., Pintó, X., & Pedro‐Botet, J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25094831 · Cited by 4
Samadder, N. J., Schroeder, M. L., Voss, M. M., Shamoun, F. E., Kullo, I. J., Curry, T. B., Houwink, E. J. F., Bublitz, M. L., Bandel, L. A., Armasu, S. M., et al. (2025) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.125.005174 · Cited by 5
Management and Consequences of Genotype-Positive Familial Hypercholesterolemia
Spinks, C., Selvaraj, M. S., Robinson, C., Peloso, G. M., Gwynne, C., Urbut, S., Truong, B. M. T., Paruchuri, K., Hornsby, W., & Natarajan, P. (2026) · JAMA Cardiology · doi:10.1001/jamacardio.2026.0006 · Cited by 4
Samuel, R., Birdsey, G., & Amerena, J. V. (2020) · Heart Lung and Circulation · doi:10.1016/j.hlc.2020.09.929 · Cited by 4
Benito‐Vicente, A., Uribe, K. B., Siddiqi, H. F., Jebari‐Benslaiman, S., Galicia-García, U., Larrea, A., Cenarro, A., Stef, M. A., Ostolaza, H., Civeira, F., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0204771 · Cited by 4
Transatlantic guidelines on dyslipidemia and cardiovascular risk: key differences across the pond
Agha, A. M., Virani, S. S., & Ballantyne, C. M. (2020) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000608 · Cited by 4
Impact of conducting a genetic study on the management of familial hypercholesterolemia
Marco-Benedí, V., Cenarro, A., Vila, À., Real, J. T., Tamarit, J. J., Álvarez-Sala, J. L., Díaz-Díaz, J. L., Perea, V., Civeira, F., & Vallejo‐Vaz, A. J. (2023) · Journal of clinical lipidology · doi:10.1016/j.jacl.2023.08.008 · Cited by 4
Fleming, J. K., Sullivan, R. M., Alfego, D., Leach, N. T., Richman, T. J., & Rafalko, J. M. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.100930 · Cited by 6
Genetic Testing for Familial Hypercholesterolemia: Health Technology Assessment.
(2022) · PubMed · Cited by 6
Screening for Hypercholesterolemia in Children: What Strategies Can Be Employed
Pyles, L. A., Elliott, E. M., & Neal, W. A. (2017) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-017-0531-z · Cited by 5
Ginger and Onion: New and Novel Considerations
Murad, S. (2018) · Pharmacy & Pharmacology International Journal · doi:10.15406/ppij.2018.06.00154 · Cited by 4
Wong, K. H. Y., Levy‐Sakin, M., Ma, W., Gonzaludo, N., Mak, A. C. Y., Vaka, D., Poon, A., Chu, C., Lao, R., Balamir, M., et al. (2019) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.1007 · Cited by 4
Familial Hypercholesterolemia: Update and Review
Chacon-Camacho, O. F., Pozo‐Molina, G., Méndez-Catalá, C. F., Reyes‐Reali, J., Méndez-Cruz, R., & Zenteno, J. C. (2021) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530321666210208212148 · Cited by 8
Familial Hypercholesterolemia: A Call for Increased Awareness in the Asian Indian Population
Wong, S., & Garg, A. (2014) · Cited by 4
Béliard, S., Rabès, J., Cariou, B., Farnier, M., Krempf, M., Ferrières, J., Danchin, N., & Bruckert, É. (2018) · La Presse Médicale · doi:10.1016/j.lpm.2018.01.025 · Cited by 7
Familial hypercholesterolaemia
Bovin, A., Kanstrup, H., & Mortensen, M. B. (2024) · Ugeskrift for Læger · doi:10.61409/v03240206 · Cited by 4
Kafol, J., Fras, Z., Novaković, M., Sperling, L. S., Cevc, M., Krevel, B., Kafol, L., Kelenc, A., Kepic, K., Vrbinc, K. N., et al. (2026) · Lipids in Health and Disease · doi:10.1186/s12944-026-02897-3 · Cited by 3
Aihaiti, X., Chen, S., Li, J., Lin, Z., Cui, Q., Xia, X., Liu, F., Shen, C., Hu, D., Huang, K., et al. (2023) · Chronic Diseases and Translational Medicine · doi:10.1002/cdt3.69 · Cited by 4
Deconinck, O. G., Sharman, J. E., Bishop, W., Lees, C. F., Dare, L., Hardikar, A., Fenton, C., Pointon, T., Watts, G. F., & Black, J. A. (2024) · Heart Lung and Circulation · doi:10.1016/j.hlc.2024.08.001 · Cited by 4
Self-citationKocejko, T. (2024) · Applied Sciences · doi:10.3390/app142311187 · Cited by 3
van Lennep, J. E. R. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.07.928 · Cited by 3
Dippel, F. W., Parhofer, K. G., Müller-Bohn, T., Gebhardt, S., & Kostev, K. (2017) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/s-0042-123977 · Cited by 3
Hipercolesterolemia familiar: experiencia en la Unidad de Lípidos de Álava
García, L. P. (2018) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2018.04.007 · Cited by 4
Lima-Martínez, M. M., Paoli, M., Vázquez-Cárdenas, A., Magaña‐Torres, M. T., Guevara, O., Muñoz, M. C., Parrilla-Alvarez, A., Márquez, Y., Medeiros, A. M., & Bourbon, M. (2017) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2017.05.007 · Cited by 3
Li, R., Xie, J., Jiang, B., Sun, Z., Wang, L., Leng, Z., Wang, Y.-L., & Yang, Y. (2021) · Texas Heart Institute Journal · doi:10.14503/thij-18-6720 · Cited by 5
Sharma, S., Khudiwal, A., Bhardwaj, S., Chaturvedi, H., & Gupta, R. (2022) · PLoS ONE · doi:10.1371/journal.pone.0269605 · Cited by 4
Maraumont, T. A.-D., Camacho-Cordero, L. M., Alva-Esqueda, M., Hernández-Garduño, A. G., Guzmán-Caniupan, J. A., & Carlos‐Rivera, F. (2022) · Cardiovascular and Metabolic Science · doi:10.35366/105819 · Cited by 3
Matsuki, K., Harada‐Shiba, M., Hori, M., Ogura, M., Akiyama, Y., Fujii, H., Ishibashi, Y., Ishida, T., Ishigaki, Y., Kabata, D., et al. (2023) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.63899 · Cited by 3
Durand, A., Morgan, C. L., Tinsley, S., Hughes, E., McCormack, T., Bitchell, C. L., & Lahoz, R. (2023) · British Journal of General Practice · doi:10.3399/bjgp.2023.0010 · Cited by 4
Yip, M.-K., Kwan, E., Leung, J. Y., Lau, E., & Poon, W. (2023) · Genes · doi:10.3390/genes14112071 · Cited by 6
Acitelli, E., Guédon, A. F., Liguori, S. D., Gallo, A., & Maranghi, M. (2024) · Endocrine · doi:10.1007/s12020-024-03763-x · Cited by 4
Screening for familial hypercholesterolemia in Sri Lanka: A laboratory-based multicenter study
Matthias, A. T., Samaranayake, T., & Saman, P. H. (2024) · International Journal of Noncommunicable Diseases · doi:10.4103/jncd.jncd_100_23 · Cited by 4
Huang, C., & Charng, M. (2019) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s193971 · Cited by 3
Dislipemias en la edad pediátrica. Importancia del diagnóstico y tratamiento precoces
Gambetta, J. C., Araujo, M. B., & Chiesa, P. (2019) · Revista Uruguaya de Cardiología · doi:10.29277/cardio.34.3.20 · Cited by 12
Carroll, C., Tappenden, P., Rafia, R., Hamilton, J., Chambers, D., Clowes, M., Durrington, P. N., Qureshi, N., & Wierzbicki, A. S. (2016) · PharmacoEconomics · doi:10.1007/s40273-016-0472-2 · Cited by 4
HERTZ, C. L., Christiansen, S. L., Ottesen, G. L., Frank-Hansen, R., Bundgaard, H., & Morling, N. (2015) · International Journal of Legal Medicine · doi:10.1007/s00414-015-1282-3 · Cited by 3
Homozygous familial hypercholesterolemia: phenotype rules!
Santos, R. D. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.03.015 · Cited by 4
Evolocumab for the treatment of homozygous familial hypercholesterolaemia
Blom, D. J., & Marais, A. D. (2016) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2016.1189323 · Cited by 3
Ferhatbegović, L., & Pojskić, B. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.06.880 · Cited by 3
Genética de la hipercolesterolemia familiar
Stoll, M., & Dell’Oca, N. (2019) · Revista Uruguaya de Cardiología · doi:10.29277/cardio.34.3.21 · Cited by 10
Genetic Polymorphisms in a Familial Hypercholesterolemia Population from North-Eastern Europe
Maștaleru, A., Cojocariu, S. A., Oancea, A., Leon, M. M., Roca, M., Zota, I. M., Abdulan, I. M., Rusu, C., Popescu, R. M., Antoci, L.-M., et al. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12030429 · Cited by 5
Genetische Erkrankungen des Lipidstoffwechsels: Schwerpunkt familiäre Hypercholesterinämie
März, W., Beil, F.-U., & Dieplinger, H. (2022) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-1516-2541 · Cited by 3
Li, F., Ye, P., Hao, Y., Du, J., Zhang, H., Wang, Z., Wang, X., Zeng, H., Ma, Y., & Lin, J. (2022) · Atherosclerosis Plus · doi:10.1016/j.athplu.2022.05.002 · Cited by 3
Gitt, A. K., Laufs, U., März, W., Paar, W. D., Bramlage, P., Marx, N., & Parhofer, K. G. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11133810 · Cited by 3
Agha, A. M., & Ballantyne, C. M. (2022) · Contemporary cardiology · doi:10.1007/978-3-030-98824-1_4 · Cited by 3
Akioyamen, L. E., Chu, A., Genest, J. J., Lee, D. S., Abdel-Qadir, H. M., Jackevicius, C. A., Lawler, P. R., Sud, M. K., Udell, J. A., Wijeysundera, H. C., et al. (2022) · CJC Open · doi:10.1016/j.cjco.2022.05.003 · Cited by 5
Genetic considerations in the treatment of familial hypercholesterolemia
Moyer, A. M., & Baudhuin, L. M. (2015) · Clinical Lipidology · doi:10.2217/clp.15.33 · Cited by 4
Role of sEH R287Q in LDLR expression, LDL binding to LDLR and LDL internalization in BEL-7402 cells
Tang, L., Wang, G., Jiang, L., Chen, P., Wang, W., Chen, J., & Wang, L. (2018) · Gene · doi:10.1016/j.gene.2018.04.038 · Cited by 3
Metadata
- Authors
- Benn, M., Watts, G. F., Tybjaerg-Hansen, A., & Nordestgaard, B. G.
- Affiliations
- University of Copenhagen (DK)
- The University of Western Australia (AU)
- The Copenhagen General Population Study (M.B., A.T.-H., B.G.N.), Herlev Hospital, Copenhagen University Hospital, DK-2730 Herlev, Denmark
- Corresponding author
- Nordestgaard, Børge G.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2012-11-01
- Volume
- 97
- Issue
- 11
- Pages
- 3956-3964
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W1993634977
- Cited by
- 632
- References
- 38
- Citations by year
- 2026: 28 · 2025: 23 · 2024: 28 · 2023: 37 · 2022: 42 · 2021: 36 · 2020: 44 · 2019: 48 · 2018: 61 · 2017: 80 · 2016: 92 · 2015: 53 · 2014: 42 · 2013: 15 · 2012: 1
- FWCI
- 36.15
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- Funders
- Amgen
- Pfizer
- AstraZeneca
- Sanofi
- Sundhed og Sygdom, Det Frie Forskningsråd
- Regeneron Pharmaceuticals
- Gentofte Hospital
- Herlev Hospital
- Medical Research Council
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- familial hypercholesterolemia, prevalence, coronary artery disease, cholesterol-lowering drugs, LDLR mutations, APOB mutations, Dutch Lipid Clinic Network criteria, underdiagnosis, undertreatment, myocardial infarction, angina pectoris, Copenhagen General Population Study
- MeSH terms
- Aged, Anticholesteremic Agents, Coronary Artery Disease, Denmark, Female, Genotype, Humans, Hyperlipoproteinemia Type II, Lipids, Lipoproteins, Male, Middle Aged, Risk, Prevalence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.